1574-7891

Molecular Oncology

Wiley (John Wiley & Sons)

View prefix report (10.1002)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 1619 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact1619 DOIs
2

Add abstracts to 592 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact592 DOIs
3

Deposit reference lists for 529 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact529 DOIs

DOIs for this ISSN

Showing the top 5 of 2926 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 The Stockholm Declaration (10.1016/j.molonc.2008.03.004)
Abstract References ORCID
102.13 22
2 Liquid biopsy: Potential and challenges (10.1016/j.molonc.2016.01.009)
Abstract ORCID
90.98 65
3 Mouse models of cancer (10.1016/j.molonc.2013.02.014)
Abstract References ORCID
88.21 14
4 Understanding the molecular mechanisms driving metastasis (10.1002/1878-0261.12024)
Abstract ORCID
87.79 56
5 Epithelial–mesenchymal transition in cancer (10.1002/1878-0261.12094)
Abstract ORCID
83.60 46
6 DNA damage response, genetic instability and cancer: From me… (10.1016/j.molonc.2011.07.006)
Abstract ORCID
80.64 40
7 Report on EU–USA Workshop: How Systems Biology Can Advance C… (10.1016/j.molonc.2008.11.003)
References ORCID
77.82 35
8 <i>Liquid biopsy</i>: from discovery to clinical implementat… (10.1002/1878-0261.12997)
Abstract ORCID
75.93 32
9 Deconstructing the molecular portraits of breast cancer (10.1016/j.molonc.2010.11.003)
ORCID
75.68 1064
10 Mutant p53 targeting by the low molecular weight compound… (10.1002/1878-0261.12065)
Abstract References ORCID
75.00 9
11 Personalized cancer medicine – A strategy to counteract an i… (10.1016/j.molonc.2012.03.002)
Abstract References ORCID
75.00 9
12 MicroRNA and cancer (10.1016/j.molonc.2012.09.006)
ORCID
74.06 916
13 <scp>FEN</scp>1 promotes tumor progression and confers cispl… (10.1002/1878-0261.12118)
Abstract ORCID
73.86 29
14 The morphologies of breast cancer cell lines in three‐dimens… (10.1016/j.molonc.2007.02.004)
ORCID
73.86 899
15 The role of histone deacetylases (HDACs) in human cancer (10.1016/j.molonc.2007.01.001)
ORCID
73.07 836
16 Cancer biomarkers (10.1016/j.molonc.2012.01.010)
ORCID
72.32 780
17 The underlying mechanism for the PARP and BRCA synthetic let… (10.1016/j.molonc.2011.07.001)
ORCID
71.85 747
18 Imaging and cancer: A review (10.1016/j.molonc.2008.04.001)
ORCID
71.11 698
19 Epithelial–mesenchymal transition in tumor metastasis (10.1002/1878-0261.12017)
ORCID
69.12 581
20 Early‐onset colorectal cancer in young individuals (10.1002/1878-0261.12417)
ORCID
68.27 537
21 Stem cells and cancer – The promise and puzzles (10.1016/j.molonc.2010.07.001)
Abstract ORCID
68.09 22
22 Dub3 controls <scp>DNA</scp> damage signalling by direct deu… (10.1002/1878-0261.12097)
Abstract References ORCID
67.73 7
23 Patient advocacy groups: Empowering patients in their fight… (10.1016/j.molonc.2007.08.003)
Abstract References ORCID
67.73 7
24 Discovery of small molecule cancer drugs: Successes, challen… (10.1016/j.molonc.2012.02.004)
ORCID
67.56 503
25 EMT and inflammation: inseparable actors of cancer progressi… (10.1002/1878-0261.12095)
ORCID
67.28 490
26 Circulating tumor cell technologies (10.1016/j.molonc.2016.01.007)
ORCID
66.64 462
27 Histological types of breast cancer: How special are they? (10.1016/j.molonc.2010.04.004)
ORCID
66.18 443
28 Histone deacetylases and cancer (10.1016/j.molonc.2012.07.003)
ORCID
64.86 392
29 Tumour heterogeneity and the evolution of polyclonal drug re… (10.1016/j.molonc.2014.06.005)
ORCID
64.38 375
30 The circ<scp>RNA</scp>–micro<scp>RNA</scp> code: emerging im… (10.1002/1878-0261.12468)
ORCID
63.85 357
31 Cancer research funding in Asia (10.1016/j.molonc.2007.06.003)
Abstract References ORCID
63.38 6
32 Frequent expression of PD‐L1 on circulating breast cancer ce… (10.1016/j.molonc.2015.05.009)
ORCID
63.13 334
33 The biology of cancer testis antigens: Putative function, re… (10.1016/j.molonc.2011.02.001)
ORCID
62.63 319
34 Targeted proteomic strategy for clinical biomarker discovery (10.1016/j.molonc.2008.12.001)
ORCID
62.35 311
35 Cell‐to‐cell communication: microRNAs as hormones (10.1002/1878-0261.12144)
ORCID
62.14 305
36 Challenges in circulating tumor cell detection by the CellSe… (10.1016/j.molonc.2015.12.002)
ORCID
62.14 305
37 HDAC inhibitor‐based therapies: Can we interpret the code? (10.1016/j.molonc.2012.09.003)
ORCID
60.82 270
38 Genetic susceptibility to breast cancer (10.1016/j.molonc.2010.04.011)
ORCID
60.78 269
39 Autophagy induction impairs migration and invasion by revers… (10.1016/j.molonc.2015.04.016)
ORCID
60.29 257
40 Unlucky number 13? Differential effects of KIT exon 13 mutat… (10.1016/j.molonc.2008.05.002)
Abstract ORCID
60.21 15
41 Triple‐negative breast cancer: Present challenges and new pe… (10.1016/j.molonc.2010.04.006)
ORCID
60.08 252
42 <i><scp>ZKSCAN</scp>1</i> gene and its related circular <scp… (10.1002/1878-0261.12045)
ORCID
59.95 249
43 Circulating tumor DNA as a non‐invasive substitute to metast… (10.1016/j.molonc.2014.12.003)
ORCID
59.46 238
44 Transfection of chimeric anti‐CD138 gene enhances natural ki… (10.1016/j.molonc.2013.12.001)
ORCID
59.32 235
45 Exosomal proteins as prognostic biomarkers in non‐small cell… (10.1016/j.molonc.2016.10.003)
ORCID
59.23 233
46 The epigenetics of breast cancer (10.1016/j.molonc.2010.04.002)
ORCID
59.18 232
47 Genetic and epigenetic alterations as biomarkers for cancer… (10.1016/j.molonc.2007.01.004)
ORCID
59.14 231
48 Biobanking for better healthcare (10.1016/j.molonc.2008.07.004)
ORCID
58.80 224
49 Mass spectrometry based biomarker discovery, verification, a… (10.1016/j.molonc.2014.03.006)
ORCID
58.80 224
50 Progression from ductal carcinoma <i>in situ</i> to invasive… (10.1016/j.molonc.2013.07.005)
ORCID
58.66 221